louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05277974: Bupivicain vs Bupivicain Plus Dexamethasone in ESP Block for Post-op Analgesia
Official title: Comparison of Bupivicain Alone With Bupivicain Plus Dexamethasone in Erector Spinae Plane Block For Post-Operative Analgesia After Thoracotomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Post Operative Pain
Keywords: Erector Spinae Plane Block, Thoracotomy, Ultrasound
Lead sponsor: Sheikh Zayed Medical College
Sponsor class: OTHER_GOV
First posted: 2022-03-14
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Thoracotomy is a very painful procedure. Different treatment modalities are being utilized for post-thoracotomy analgesia including I/V NSAID, Opoids and Neuropathic medications. Other techniques commonly utilized include Thoracic epidural, Paravertebral block; but both are associated with significant failure rate and other complications. Ultrasound guided Erector Spinae Plane block is a new regional anesthesia technique that provides analgesia at multidermatomal levels acriss the posterior, lateral and anterior thoracic walls. The rational of my study is that it is a novel technique and studies with bupivicain alone are present but no study was found with bupivicain plus dexamethasone.


Eligibility criteria: Inclusion Criteria:

* age 18-60years ASA I-III Patients undergoing elective thoracotomies

Exclusion Criteria:

* Refusal of Patient Coagulation disorders Known Allergy to Local Anesthetics Infection at the site of injection Pregnant females Morbid Obesity(BMI\>40kg/m2) Psychiatric illness Diabetic Patients.

Primary outcomes:
measure: postoperative pain scores
timeFrame: 36 hours postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Rahim yar khan
country: Pakistan
facility: Sheikh Zayed Medical College/Hospital Rahim Yar Khan
state: Punjab
city: Rahim yar khan
country: Pakistan
facility: Sheikh Zayed Medical College/Hospital
state: Punjab
Study officials:
affiliation: Assistant Professor
name: amjad siddique, FCPS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04856774: Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Official title: A Multicenter, Open-Label, Phase Ib/II Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Tumors
Lead sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-04-23
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study was to assess the safety, tolerability, and efficacy when combining SHR-1701 and BP102 in participants with certain cancers. This study was conducted in 2 phases, Phase Ib and Phase II.


Eligibility criteria: Inclusion Criteria:

1. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative measures do not exist or are no longer effective (phase Ib)
2. Histologically or cytologically confirmed metastatic or locally advanced solid tumors of the selected indications. (Phase II).
3. .Life expectancy exceeds 12 weeeks;
4. The Eastern Cancer Cooperative Group (ECOG) has a performance score of 0 or 1;
5. Normal organ and marrow function;

Exclusion Criteria:

1. Has known active central nervous system (CNS) metastases. Subjects with previously treated brain metastases may participate provided they are stable.
2. A history of human immunodeficiency virus (HIV) infection is known, or has an active autoimmune disease.
3. History of interstitial lung disease or pneumonia requiring oral or intravenous steroids.
4. Has moderate or severe cardiovascular disease;
5. Active HBV(hepatitis B) or HCV (Hepatitis C virus)-infected subjects;
6. Any other malignancies within 5 years except for those with negligible risk of metastasis or death.

Primary outcomes:
measure: recommended phase 2 dose (Phase Ib)
timeFrame: At the end of Cycle 2 (each cycle is 21 days)
measure: Objective response rate (ORR)
timeFrame: 2 years
Secondary outcomes:
measure: Dose Limiting Toxicity (DLT) (Phase 1b)
timeFrame: At the end of Cycle 2 (each cycle is 21 days)
measure: Number of participants with treatment emergent adverse events (TEAEs)
timeFrame: For each participant, from the first dose till 90 days after the last dose
measure: Number of participants with treatment emergent serious adverse events (SAEs)
timeFrame: For each participant, from the first dose till 90 days after the last dose
measure: ORR
timeFrame: 2 years
measure: Duration of response (DOR)
timeFrame: 2 years
measure: Disease control rate (DCR)
timeFrame: 2 years
measure: Time to response(TTR)
timeFrame: 2 years
measure: Progression-free survival (PFS)
timeFrame: 2 years
measure: Overall survival (OS)
timeFrame: 2 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangzhou
Study officials:
References:
Clinical trial NCT03474874: Human Repeated Insult Patch Test
Official title: Human Repeated Insult Patch Test
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dermatitis
Allergy
Contact Allergy
Lead sponsor: NeXtGen Biologics, Inc.
Sponsor class: INDUSTRY
First posted: 2018-03-23
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Repeated insult patch test on healthy males and females to determine potential contact irritation or contact allergy in the skin


Eligibility criteria: Inclusion Criteria:

* Adults;
* Subjects must understand and execute an Informed Consent Form that includes a HIPAA statement;
* Subjects must be considered dependable and able to follow directions

Exclusion Criteria:

* Subjects who are in ill health;
* Subjects who are taking medications other than birth control;
* Female subjects who are pregnant (return positive urine pregnancy test), planning to become pregnant or lactating during the course of the trial;
* Subjects who have a history of adverse reactions to personal care products, or known sensitivity to the test materials or their constituents including patch materials;
* Subjects with any active skin disease;
* Subjects who have heavy alcohol consumption;
* Subjects with current use or history of repeated use of street drugs;
* Subjects with a significant past medical history to potentially effect results of study;
* Subjects with immunization less than 10 days prior to the test patch application;

Primary outcomes:
measure: Erythema at the Patch Test Site is Evaluated for Each Participant
timeFrame: 3 weeks
Secondary outcomes:
measure: Sensitization Reactions
timeFrame: 5 weeks
Other outcomes:
Locations:
city: Fairfield
country: United States
facility: Consumer Product Testing Company, Inc.
state: New Jersey
Study officials:
References:
Clinical trial NCT05970874: Evaluation of Hand Grip Strength in Pregnant COVID-19 Patients
Official title: Musculoskeletal Pain in Pregnant Infected With COVID-19, Evaluation of Fatigue and Muscle Grip Strength
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Pregnancy Related
Keywords: COVID-19
Musculoskeletal Symptom
Hand Grip Muscle Streng
Lead sponsor: Karaman Training and Research Hospital
Sponsor class: OTHER
First posted: 2023-08-01
Enrollment: 23
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: pregnant covid 19 patients

Brief summary: It was presented as a cross-sectional, single-center, retrospective case series. Pregnant women with a positive Polymerase Chain Reaction (PCR) diagnosis of Covid 19 were included in the study. The relationship between patients' musculoskeletal symptoms and signs and hand grip strength was investigated.

Detailed description: Covid 19 is the disease defined for strains infected with severe acute respiratory syndrome coronavirus 2(Sars-CoV-2). Hand grip strength is a non-invasive, easily applicable, objective parameter. It was presented as a cross-sectional, single-center, retrospective case series. Pregnant women with a positive Polymerase Chain Reaction (PCR) diagnosis of Covid 19 were included in the study. The relationship between patients' musculoskeletal symptoms and signs and hand grip strength was investigated.

Eligibility criteria: Inclusion Criteria:

* Pregnant women with a positive Polymerase Chain Reaction (PCR) diagnosis of Covid 19

Exclusion Criteria:

* Those with orthopedic defects in the dominant hand and wrist and those with hand, wrist and shoulder involvement on the side of the measurement related to rheumatological diseases were excluded from the study.

Primary outcomes:
measure: Hand grip strength assessment
timeFrame: The first 24 hours after admission to the service.
Secondary outcomes:
measure: symptoms
timeFrame: The first 24 hours after admission to the service.
measure: laboratory findings
timeFrame: The first 24 hours after admission to the service.
measure: Vaccine
timeFrame: pre-infection period was questioned
measure: Smoking
timeFrame: pre-infection period was questioned
Other outcomes:
Locations:
city: Karaman
country: Turkey
facility: Hatice Toprak
state: Merkez
Study officials:
affiliation: dr.tprk@hotmail.com
name: Hatice Toprak
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03684174: Non-Contact Air Tonometry (Topcon CT-1®) Versus Goldmann
Official title: Non-Contact Air Tonometry (Topcon CT-1®) Versus Goldmann Applanation Tonometry: a Device Comparison Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glaucoma
Keywords: Tonometry
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2018-09-25
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy volunteers

Brief summary: In this prospective device comparison study with 58 healthy eyes, the Topcon CT-1® showed statistically significant elevated intraocular pressure measurements compared to the gold standard Goldmann application tonometry.

Detailed description: Introduction:

Intraocular pressure (IOP) measurement is crucial in glaucoma diagnosis and treatment. We compared a non-contact air tonometer (Topcon CT-1®) with the gold standard Goldmann Applikation tonometer (GAT).

Methods:

In this prospective, mono centric device comparison study, only healthy eyes were enrolled. IOP was measured three times with the Topcon CT-1® followed by three times GAT. Mean IOP was calculated and compared with a paired t-test, a linear regression and a Bland-Altman analysis.

Eligibility criteria: Inclusion Criteria:

Healthy volunteers who agreed to be included in the study and were able to comply with the measurement procedures

Exclusion criteria were cor-neal abnormalities (such as oedema, scars or dystrophies, astigmatism,hyperopia or myopia \> 3 dioptres), a history of ocular surgery or recent(\<47 weeks) ocular disorder.

Primary outcomes:
measure: Comparison of GAT with air tonometry Topcon CT1
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Wettingen
country: Switzerland
facility: Augenpraxis Centerpassage
state: AG
Study officials:
affiliation: University of Zurich
name: Pascal B Knecht, MD PD
role: STUDY_CHAIR
References:
citation: Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. doi: 10.1001/archopht.120.6.714.
citation: Jorge J, Gonzalez-Meijome JM, Diaz-Rey JA, Almeida JB, Ribeiro P, Parafita MA. Clinical performance of non-contact tonometry by Reichert AT550 in glaucomatous patients. Ophthalmic Physiol Opt. 2003 Nov;23(6):503-6. doi: 10.1046/j.1475-1313.2003.00139.x.
citation: Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003 Jan;121(1):48-56. doi: 10.1001/archopht.121.1.48.
citation: Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 Mar;90(3):262-7. doi: 10.1136/bjo.2005.081224.
Clinical trial NCT05216874: The Effect of Splint Usage in Laterognathic Cl III Orthognathic Surgery Patients
Official title: The Effect of Splint Usage in Laterognathic Cl III Orthognathic Surgery Patients: Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Skeletal Malocclusion
Class III Malocclusion
Laterognathia
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2022-02-01
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Preoperative occlusal splint treatment Cl III Laterognathia patients
Primary purpose: PREVENTION

Brief summary: It is crucial to maintain the anatomic condylar positions during orthognathic surgery. Condylar positions are affected directly under general anesthesia because of joint and muscle relaxation. Possible unwanted changes in the joint position may cause incorrect positioning of the jawbones. This could affect the success of the surgery in terms of function and facial aesthetics causing the need for a second surgery. Our aim is to evaluate whether the use of MR Splint has a statistically significant effect on muscle relaxation-induced condyle position deviations under general anesthesia in Class III Laterognathia patients.

Detailed description: It is crucial to maintain the anatomic condyle positions during orthognathic surgery to prevent iatrogenic temporomandibular joint complications. Condyle shunts are affected directly under general anesthesia because of the joint and muscle relaxation. Surgical guidance appliances are prepared according to the TMJ records taken chairside while patients are in an upright position. During surgery, these appliances are applied in a supine position while the muscles are relaxed. Postoperative and long-term effects of TMJ and muscle relaxation obtained under general anesthesia in class III and asymmetric patients will be examined. Patients who had occlusal splint before records taken will be evaluated in terms of condyle location by MPI.

Our aim is to evaluate whether the use of MR Splint has a statistically significant effect on muscle relaxation-induced condyle position deviations under general anesthesia in Class III Laterognathia patients.

Eligibility criteria: Inclusion Criteria:

* being ready for orthognathic surgery
* must be able to give centric relation records

Exclusion Criteria:

* having any TMDsyndromes
* cleft lip and palate,
* have bruxism,
* TMJ or muscle disfunctions,
* under any medication of muscle relaxants,
* narcotics and antidepressants,
* usage of removeable prosthetics
* have toothless areas that can affect the wax impression for centric record
* used horizontal elastics within the last 2 months

Primary outcomes:
measure: MPI Records for Splint Users
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fatih
country: Turkey
facility: Banu Kılıç
state: İstanbul
Study officials:
affiliation: Bezmialem Vakıf Üniversitesi
name: Banu Kılıç, asst. prof
role: STUDY_DIRECTOR
References:
Clinical trial NCT01970774: Medication Therapy Management With Pharmacogenetic Testing
Official title: Assessing Feasibility and Utility of Enhancing Medication Therapy Management With Pharmacist-Delivered Pharmacogenetic Testing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pharmacogenetics
Medication Therapy Management
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2013-10-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to investigate the benefit and feasibility of providing pharmacogenetic (PGx) testing as part of a standard medication therapy management (MTM) session for patients taking multiple medications, a high-risk population for adverse drug reactions and non-response. Research participants will attend two MTM sessions and undergo PGx testing to inform the MTM plan. Participants will also complete 2 surveys pre and post-MTM/PGx testing. Data analysis will assess the impact of MTM/PGx testing on recommendations for drug dosing, clinical outcomes, patient satisfaction, and feasibility of service delivery. Safety issues are minimal with the primary risks being associated with loss of confidentiality, typical discomfort associated with acquiring blood samples, and genetic discrimination.


Eligibility criteria: Inclusion Criteria:

* currently prescribed 3 medications, one of which must be simvastatin or clopidogrel
* 18 years of age or older
* English speaking
* patients of Mahesh Patel or William Kraus at Duke Southpoint Clinic

Exclusion Criteria:

* if patient has ever had MTM or PGx

Primary outcomes:
measure: Patient satisfaction with MTM and PGx
timeFrame: 3 months after completion of MTM2
measure: Change in clinical biomarkers associated with drug therapy
timeFrame: baseline and 2 months
measure: Number of recommended drug selection/dosing adjustments
timeFrame: approximately 9 months
Secondary outcomes:
measure: Physician time to perform MTM and PGx
timeFrame: end of study, approx. 9 months
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke Health Center at Southpoint
state: North Carolina
Study officials:
affiliation: Duke University
name: Susanne Haga, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04135274: Is Neutrophil to Lymphocyte Ratio a Prognostic Factor of Sepsis in Newborns With Operated Neural Tube Defects?
Official title: Is Neutrophil to Lymphocyte Ratio a Prognostic Factor of Sepsis in Newborns With Operated Neural Tube Defects?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neural Tube Defects
Newborn Sepsis
Lead sponsor: Tepecik Training and Research Hospital
Sponsor class: OTHER
First posted: 2019-10-22
Enrollment: 57
Sex: ALL
Maximum age (years): 28
Standard ages: CHILD
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: \< 28 days infants

Brief summary: We aimed to investigate whether Neutrophil Lymphocyte Ratio is a Prognostic Factor of Sepsis in Newborns with operated Neural Tube Defects?


Eligibility criteria: Inclusion Criteria:

* \<28 days diagnosed with with neural Tüpe Defects To be operated

Exclusion Criteria:

* \>28 days

Primary outcomes:
measure: Neutrophil to lymphocyte ratio is prognostic faktör for Sepsis
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01940874: Cerebral Oxymetry at Elective Coronary and Valve Surgery.
Official title: Cerebral Oxymetry at Elective Coronary and Valve Surgery: An Observational Study Using Norepinephrine to Maintain Arterial Blood Pressure on Cardio Pulmonary Bypass.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease.
Aortic Valve Stenosis.
Aortic Valve Regurgitation.
Keywords: Cerebral Oximetry.
Aortic valve stenosis.
Aortic valve regurgitation.
Coronary artery disease.
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2013-09-12
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We want to include 50 patients, both women and men, undergo elective coronary bypass surgery or valve surgeon in CPB with moderate hypothermia.

Brief summary: Use of vasopressor to maintain Mean Arterial Pressure on Cardio Pulmonary Bypass can lead to decreased cerebral flow and oxygenation in individual patients and this can be detected by means of cerebral oxymetry.


Eligibility criteria: Inclusion Criteria:

* Patient age under 80.
* Patients should undergo elective coronary artery bypass grafting surgery (ACB) or heart valve surgery (AVR or MVR).
* The patient must be admitted at least 18 years of years.

Exclusion Criteria:

* Damage to the frontal lobes corresponding to the area where SCO2 monitored.
* Patients in pharmacological studies.
* Patients with known intracranial vascular anomalies or cerebral aneurysms.
* Patients with known neurological disease.
* Patients with known undergone cerebral insult, TIA or carotid stenosis.

Primary outcomes:
measure: Cerebral oxymetry values
timeFrame: March 2013
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
affiliation: Oslo Ùniversity Hospital
name: Ove A. Hagen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02632474: ART Drug Dosage Adjustment in HIV-infected Population
Official title: ART Drug Dosage Adjustment Using FSCII in Chinese HIV-infected Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: HIV Infections
Keywords: HIV Infections
Tenofovir
Efavirenz
Lead sponsor: Shanghai Public Health Clinical Center
Sponsor class: OTHER_GOV
First posted: 2015-12-16
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine efficacy of the combination of low dose of Tenofovir, Efavirenz and Lamivudine in treating HIV-infection.

Detailed description: The feedback system control (FSC) technique has been developed to rapidly identify optimal combinations for therapeutic purposes. Low dose of TDF+3TC+EFV combination has been test in vitro study by FSC which showed high efficacy and now the investigators apply it to human to further optimize the ART combination.

Eligibility criteria: Inclusion Criteria:

* HIV antibody positive
* HIV RNA below 10\*E5 copies/ml
* CD4 T cell count above 200 cells/ml
* Provision of written informed consent

Exclusion Criteria:

* HIV genotyping resistant to investigating drug
* Pregnant, breastfeeding, or lactating
* Any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with treatment, assessment, compliance with the protocol, or subject safety. This would include any active clinically significant renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease) illness, or malignancy
* Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol
* Laboratory blood values:
* Haemoglobin \<7.0 grams/decilitre (g/dL)
* Neutrophil count \<500/mm3
* Platelet count \<50,000/mm3
* Aspartate aminotransferase or Alanine transaminase \>5 times Upper Limit of Normal (ULN)
* Subjects with an estimated creatinine clearance of \<50 mL/minute

Primary outcomes:
measure: HIV viral load
timeFrame: 48 weeks
Secondary outcomes:
measure: CD4 Count
timeFrame: 48 weeks
Other outcomes:
measure: Drug Plasma Concentration
timeFrame: Day 7,14,21,28
Locations:
city: Shanghai
country: China
facility: Shanghai Public Health Clinical Center
state: Shanghai
Study officials:
References: